G-6GWX7GB3GG, GT-M69MZWP
x

Member Login

CIRC End of Grant Report

End of Grant Report

Please use the fields below to describe the difference your research is making during this reporting period. Your responses are incredibly important as they help convey the value and importance of your research to CIRC members and sponsors. Providing responses as specific and detailed as possible helps us to understand your progress, promote your research, and help our members and sponsors under the impact of research overall.

STUDY DETIALS

Name of PI and Co-PI(s)(Required)
First Name
Last Name
 
Email(Required)
Please provide an email address for the confirmation of submission to be sent to.

SUMMARY OF PROJECT PROGRESS

Your report in this section will be kept confidential, and will not be shared with members, sponsors, or the public.
Summarize the research performed. 500 words maximum (approximately 3,000 characters) (Do not exceed 3500 characters, including spaces).
List the key milestones and timelines indicated in your original grant proposal. We encourage you to use bullet points in your response. 500 words maximum (approximately 3,000 characters).
Describe how these key milestones were met. If any milestones were not met, please describe why. We encourage you to use bullet points in your response. 250 words maximum (approximately 1,500 characters).
B) Is this research continuing once the Crohn’s and Colitis Canada grant ends? Has this project inspired future research studies? Please describe. 250 words maximum (approximately 1,500 characters).
b) Have you received additional funding (from other sources) to support or continue this project? Please include funding source, term, and $ amount. 250 words maximum (approximately 1,500 characters).

2. REPORTING PROJECT PROGRESS TO CIRC SPONSORS

Your report below will NOT be kept confidential, and may be shared with members, sponsors, or the public.
Summarize in simple, non-technical language the research that has been performed and any findings identified during this reporting period. When completing this section, write it in the same language you would use to describe your project to a CIRC sponsor. 250 words maximum (approximately 1,500 characters) (Do not exceed 2000 characters, including spaces).
In 2-3 sentences, what is the biggest achievement of your research that we can communicate to our sponsors? 100 words maximum (approximately 600 characters).
How do you anticipate this research will improve the lives of people living with IBD? 100 words maximum (approximately 600 characters).
What is the potential for your research 10 years down the road? What can this research lead to? 100 words maximum (approximately 600 characters) (Do not exceed 800 characters, including spaces).
Please answer each of the following (as applicable):a) Fundamental knowledge (e.g. development of new knowledge and/or scientific methods) b) Influencing other researchers (e.g. cited in relevant scientific literature) c) Influencing policy (e.g. research cited in policy documents or advocacy publications) d) Influencing health care practice and program delivery (e.g. research cited in health professional education material, in clinical and service guidelines or used in program development) e) On the training of new researchers (e.g. research cited in textbooks or reading lists).We encourage you to use bullets. No word limit.
Describe the impact of CIRC's cumulative funding of your research to date, addressing in particular the following:a) Impact on finding the cures and/or improving the quality of life of people living with Crohn’s disease or ulcerative colitis b) How your research has impacted advancing IBD research and knowledge pool c) Gaps filled by your research1,000 words maximum (approximately 6,000 characters).

3. KNOWLEDGE TRANSLATION & EXCHANGE

Please list all KTE activities that have NOT been reported in previous years’ annual progress reports.
Please indicate how patients with Crohn’s and colitis, or members of the public have been involved in the planning, conduct, interpretation or dissemination of your research to date. Please list the number of patients or members of the public that have been involved, and describe their role in the study. Do not include patients recruited as research subjects. 250 words maximum (approximately 1,500 characters) (Do not exceed 2000 characters, including spaces.)
Does your research involve First Nations, Métis, or Inuit peoples or communities? If so, please describe how members of these communities were involved in the planning, conduct, interpretation or dissemination of your research to date. 250 words maximum (approximately 1,500 characters) (Do not exceed 2000 characters, including spaces.)
Describe the role of sex and gender in your research and how you have addressed sex and gender in your research to date. 250 words maximum (approximately 1,500 characters) (Do not exceed 2000 characters, including spaces.)
What topics may we call on you to speak about to members and sponsors? 250 words maximum (approximately 1,500 characters)
(e.g. invited speaking engagements, poster presentations, abstracts, etc) Please list all presentations directly related to this project. Presentations listed in previous years’ annual progress reports should NOT be included unless there are updates. Please specify the type of presentations. No word limit.
VI. SCIENTIFIC PROTOCOL REGISTRATION(Required)
Please indicate whether your study protocol has been registered or published in any public forum (e.g. ClinicalTrials.gov, PROSPERO, journal publication, public repository or website).
Do you anticipate any commercialization possibilities in the future? Please describe. 250 words maximum (approximately 1,500 characters) (Do not exceed 2000 characters, including spaces.)
Please click on the button below to download the Financial Report Template.Follow the instructions in the document and upload the completed and signed Statement of Account page (PDF), along with the completed version of the excel file.
Drop files here or
Accepted file types: xlsx, pdf, Max. file size: 64 MB, Max. files: 2.
    This field is for validation purposes and should be left unchanged.